Echo At A Glance

Echo's Symphony™ tCGM System is a next-generation, non-invasive (needle-free), wireless, tCGM system for use in diabetes home use and hospital critical care markets.  Symphony incorporates Echo's patented feedback mechanism for optimal control of skin permeation and its non-invasive transdermal biosensor technologies. With Symphony, Echo is focused on reducing reliance on point-of-care periodic finger-stick glucose testing by providing reliable, on-demand glucose data continuously, conveniently and cost-effectively. Echo's goal is to change the current paradigm of invasive, episodic glucose testing in diabetes home use and hospital critical care settings with a reliable, needle-free and easy-to-use tCGM system that can improve patient compliance and achieve better overall glucose control throughout the day and night. 

Echo's is leveraging it AzoneTS™ skin penetration technology to develop a wide-variety of new transdermal reformulations of pharmaceutical products previously approved by the FDA. Echo has submitted a New Drug Application (NDA) to the FDA covering its lead AzoneTS-reformulated product candidate, Durhalieve™, for treatment of corticosteroid responsive dermatoses. Echo is also focused on Phase 2 development of Durhalieve for keloid scarring. Echo is developing additional AzoneTS™ product candidates in accordance with the FDA's Section 505(b)(2) guidelines.